Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
about
Potential Clinical and Economic Impact of Switching Branded Medications to Generics.Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjectsConcerns about the safety of obesity agents from a manufacturing perspective.Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.Pharmacokinetic basis of the antiplatelet action of prasugrel.Impact of preformulation on drug development.Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions.Physicochemical and in vitro mucoadhesive properties of microparticles/discs of betamethasone for the management of oral lichen planus.In-vitro evaluation of performance of solid immediate release dosage forms of weak bases in upper gastrointestinal lumen: experience with miconazole and clopidogrel salts.Bioequivalence study of four different trademarks of enalapril maleate in spontaneously hypertensive rats.Issues with generic drugs in Saudi Arabia.Salt Selection Matters: Differential Renal Toxicity With MDV1634.Maleate Versus MDV1634.2HCl.
P2860
Q33637817-7375A6FB-371C-4DB7-9F81-8AE07E020F53Q34614739-1B4083A9-8528-41D4-AD2A-E230E2AD6545Q35694495-07F01917-6213-4C89-BE64-BFB589C4826AQ37226385-B284719D-DE40-4ECB-A362-D11EF73A8E14Q37269872-177DD91D-CFC2-4C95-A6B3-45D3EA69A581Q37321407-ECD82682-B1E0-494E-835C-5AC1B98F985EQ37927151-ECBA887B-F603-4ECD-98D2-76F39BBD7B43Q38093663-1E2F0CCF-EA8B-404A-9166-C47588E3D53DQ39460911-0C1AF838-739C-49D3-9FC3-38CA980D0D3EQ40492373-106B7A1E-43BE-44BF-A9D3-72FD2A9B16DEQ41132412-E201D837-E275-4CCA-A8D4-A9CBBD6B7092Q46677095-7B73B62B-FC6A-4113-BAA4-E3C39CD2C7A9Q53234388-1974BC66-7CAE-4AEE-AEB4-8076669114EAQ53835934-B967F24E-BD39-4AF9-B0D9-ED3419A42942
P2860
Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Generic substitution: the use ...... tions for safety and efficacy.
@ast
Generic substitution: the use ...... tions for safety and efficacy.
@en
type
label
Generic substitution: the use ...... tions for safety and efficacy.
@ast
Generic substitution: the use ...... tions for safety and efficacy.
@en
prefLabel
Generic substitution: the use ...... tions for safety and efficacy.
@ast
Generic substitution: the use ...... tions for safety and efficacy.
@en
P2093
P1476
Generic substitution: the use ...... tions for safety and efficacy.
@en
P2093
P356
10.1016/J.EJPS.2005.12.001
P407
P577
2006-01-18T00:00:00Z